title: Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.
abstract: Hantavirus pulmonary syndrome (HPS) is a severe disease caused by hantavirus infection of pulmonary microvascular endothelial cells leading to microvascular leakage, pulmonary edema, pleural effusion and high case fatality. Previously, we demonstrated that Andes virus (ANDV) infection caused up-regulation of vascular endothelial growth factor (VEGF) and concomitant downregulation of the cellular adhesion molecule VE-cadherin leading to increased permeability. Analyses of human HPS-patient sera have further demonstrated increased circulating levels of VEGF. Here we investigate the impact of a small molecule antagonist of the VEGF receptor 2 (VEGFR-2) activation in vitro, and overall impact on survival in the Syrian hamster model of HPS.
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Brian H
authors.initials: BH
authors.lastname: Bird
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Punya
authors.initials: P
authors.lastname: Shrivastava-Ranjan
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Dodd
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Bobbie R
authors.initials: BR
authors.lastname: Erickson
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. Electronic address: ccs8@cdc.gov.
authors.forename: Christina F
authors.initials: CF
authors.lastname: Spiropoulou
mesh_terms: D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D006224:Cricetinae; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000821:virology; D006476:Orthohantavirus / Q000187:drug effects* / Q000502:physiology*; D018804:Hantavirus Pulmonary Syndrome / Q000378:metabolism / Q000401:mortality / Q000821:virology*; D010766:Phosphorylation / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D019562:Viral Load
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; C452423:vandetanib
keywords: Andes virus; Animal model; Antiviral; Bunyaviridae; Hantavirus pulmonary syndrome; Hemorrhagic fever; Tyrosine kinase inhibitor; Vandetanib; Vascular endothelial growth factor